Effectiveness of Pretreatment in Decreasing Adverse Events Associated with Pamidronate in Children and Adolescents

Pharmacotherapy

Volumn 24, Issue 2 I, 2004, Pages 195-197

  Robinson, Renee F ^a,b,c,e   Nahata, Milap C ^a,b   Hayes, John R ^d   Batisky, Donald L ^a,c   Bates, Carlton M ^a,c   Mahan, John D ^a,c  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e NONE   (United States)

Author keywords

Acetaminophen; Aminobisphosphonate; Bone density; Bone resorption; Ibuprofen; Juvenile osteoporosis; Osteogenesis imperfecta; Pamidronate; Pretreatment

Indexed keywords

IBUPROFEN; PAMIDRONIC ACID; PARACETAMOL;

ADOLESCENT; ADULT; BONE DENSITY; BONE DYSPLASIA; BONE PAIN; CHILD; CLINICAL ARTICLE; DIZZINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; FEVER; HUMAN; JUVENILE OSTEOPOROSIS; LEUKOPENIA; MALE; NAUSEA; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; REVIEW;

ABDOMINAL PAIN; ACETAMINOPHEN; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; IBUPROFEN; INJECTIONS, INTRAVENOUS; MALE; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PREMEDICATION; RETROSPECTIVE STUDIES;

EID: 1142310726     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.2.195.33143     Document Type: Review

References (14)

1. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001;160(11):641-4.
2. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001;14(5):529-33.
3. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002;86(5):356-64.
4. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998;87(1):64-8.
5. Dent CE. Osteoporosis in childhood. Postgrad Med J 1977;53(622):450-7.
6. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979;16(2):101-16.
7. Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 1996;45(3):175-9.
8. Williams CJ, Smith RA, Ball RJ, Wilkinson H. Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. Arch Dis Child 1997;76(2):169-70.
9. Novartis Pharmaceuticals Corporation. Aredia for injection (pamidronate) package insert. East Hanover, NJ; May 1998.
10. Bittar N. Maintaining long-term control of blood pressure: the role of improved compliance. Clin Cardiol 1995;18(6 suppl 3):111-12-16.
11. Fincke BG, Miller DR, Spiro A III. The interaction of patient perception of overmedication with drug compliance and side effects. J Gen Intern Med 1998;13(3):182-5.
12. Berry DC, Michas IC, Bersellini E. Communication information about medication side effects: effects on satisfaction, perceived risk to health, and intention to comply. Psychol Health 2002;17(3):247-67.
13. Bailey BJ, Carney SL, Gillies AH, McColm LM, Smith AJ, Taylor M. Hypertension treatment compliance: what do patients want to know about their medications? Prog Cardiovasc Nurs 1997;12(4):23-8.
14. Russell RG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999;9(suppl 2):S66-80.